Patents by Inventor Luis David Jaramillo

Luis David Jaramillo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250236887
    Abstract: Described herein are optimally-modified GJB2 cDNA and associated genetic elements for use in recombinant adeno-associated virus (rAAV)-based gene therapy for the treatment of genetic hearing loss.
    Type: Application
    Filed: January 17, 2025
    Publication date: July 24, 2025
    Inventors: Christopher Bartolome, Luis David Jaramillo, Adrian M. Timmers, Steven Pennock, Mark Shearman
  • Patent number: 12241077
    Abstract: Described herein are codon optimized nucleic acid sequences encoding gap junction protein beta 2 (GJB2), and associated genetic elements, for use in recombinant adeno-associated virus (rAAV)-based gene therapy. The rAAV vectors through which GJB2 is packaged can be used for targeted delivery to patients suffering from genetic hearing loss, including patients with autosomal mutations, recessive or dominant, in the GJB2 gene.
    Type: Grant
    Filed: September 30, 2020
    Date of Patent: March 4, 2025
    Assignee: Eli Lilly and Company
    Inventors: Christopher Bartolome, Luis David Jaramillo, Adrian M. Timmers, Steven Pennock, Mark Shearman
  • Publication number: 20210095313
    Abstract: Described herein are optimally-modified GJB2 cDNA and associated genetic elements for use in recombinant adeno-associated virus (rAAV)-based gene therapy for the treatment of genetic hearing loss.
    Type: Application
    Filed: September 30, 2020
    Publication date: April 1, 2021
    Inventors: Chris Bartolome, Luis David Jaramillo, Adrian Timmers, Steven Pennock, Mark Shearman